Clinical & Translational Oncology Journal Citation Rate 2026

ISSN 1699-048X eISSN 1699-3055 Springer Science+Business Media ES

Q2 Quartile Established Impact

About Clinical & Translational Oncology
{# Self-contained "answer block": one dense, LLM-quotable paragraph stating every core fact with an explicit as-of year, server-rendered and unique per journal. This is the canonical fact statement — other sections add narrative, they do not restate these numbers. #}

Clinical & Translational Oncology (CTO) is a peer-reviewed academic journal covering Breast Cancer Treatment Studies and Cancer Immunotherapy and Biomarkers, published by Springer Science+Business Media in ES, catalogued under ISSN 1699-048X (e-ISSN 1699-3055). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 2.27 (Q2 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$4290 USD).

Clinical & Translational Oncology Citation Rate 2026 — In Context

Clinical & Translational Oncology has a 2025 2-Year Citation Rate (OpenAlex) of 2.27, placing it in the Q2 quartile within the Breast Cancer Treatment Studies research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.

Clinical & Translational Oncology operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.

Researchers looking to publish in Clinical & Translational Oncology should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Clinical & Translational Oncology against similar journals in the field, use our journal comparison tool.

Submission Tips for Clinical & Translational Oncology
  • Budget $4290 for the Article Processing Charge. Check if your institution or funder covers OA fees.
  • This journal covers Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Clinical & Translational … Compares
Citation Rate vs Field Avg
-9%
Field avg: 2.48
APC vs Field Avg
+59%
Field avg: $2706

Compared against 22 journals in the same research areas.

ISSN (Print) 1699-048X
ISSN (Online) 1699-3055
Publisher Springer Science+Business Media
Country Spain
APC / Cost $4290 USD
In-depth profile & metrics

Clinical & Translational Oncology is published by Springer Science+Business Media and based in Spain. It runs on a subscription or hybrid model with an article-processing charge of USD 4290.

In our subject taxonomy, Clinical & Translational Oncology is classified under Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies and Lung Cancer Diagnosis and Treatment.

Clinical & Translational Oncology is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.

Its most recent citation rate stands at 2.266.

Research Areas
Links
Frequently Asked Questions about Clinical & Translational Oncology

Clinical & Translational Oncology does not hold a Clarivate (JCR) Impact Factor on JournalsHub. Its 2-year citation rate, computed from OpenAlex open citation data, is 2.266 — an open proxy for citation impact, not the licensed JCR Impact Factor.

No, Clinical & Translational Oncology is not an open access journal.

The Article Processing Charge (APC) for Clinical & Translational Oncology is $4290 USD.

Clinical & Translational Oncology is published by Springer Science+Business Media.

Clinical & Translational Oncology shows strong legitimacy signals: it is indexed in OpenAlex. Indexing in recognised databases such as Scopus and DOAJ is a reliable indicator of a peer-reviewed, non-predatory journal, because predatory titles are typically excluded from them. Always confirm the journal's scope and editorial board fit your work before submitting.

The ISSN of Clinical & Translational Oncology is 1699-048X. Its electronic ISSN (eISSN) is 1699-3055.

Clinical & Translational Oncology sits in the Q2 quartile based on its latest impact factor of 2.27, ranked across all journals in our database.
Live Indexing Status
Updated April 2026

Track real-time indexing metrics to ensure this journal meets your academic requirements.

OpenAlex
Verified
DOAJ
Non-OA
Predatory Check
Clean
Citation Rate
2.266
2-Year Citation Rate (OpenAlex) · 2025
Historical Trend
Initial data points only
Citation Rate by Year
Year Value Source
2025 2.266 2-Year Mean Citedness (OpenAlex)

Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.

Compare Journals

Compare Clinical & Translational Onco… against similar publications in its field:

Related Journals in Your Field

Metadata

Last updated: Apr 24, 2026

Updated by: openalex_bulk

OpenAlex ID: S179824187

Get weekly updates for Breast Cancer Treatment Studies journals

Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.

Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now
Compare 0 Open → Clear
Save your viewing history
You've browsed several journals this session. Sign in to track them in one place and get weekly impact-factor updates.
Save with Google